SG10201603721TA - Anti-CTLA-4 Antibodies - Google Patents

Anti-CTLA-4 Antibodies

Info

Publication number
SG10201603721TA
SG10201603721TA SG10201603721TA SG10201603721TA SG10201603721TA SG 10201603721T A SG10201603721T A SG 10201603721TA SG 10201603721T A SG10201603721T A SG 10201603721TA SG 10201603721T A SG10201603721T A SG 10201603721TA SG 10201603721T A SG10201603721T A SG 10201603721TA
Authority
SG
Singapore
Prior art keywords
ctla
antibodies
anti
Prior art date
Application number
SG10201603721TA
Inventor
Cheng-I Wang
Eve Ngoh
Siok Ping Yeo
Original Assignee
Agency Science Tech & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res filed Critical Agency Science Tech & Res
Priority to SG10201603721TA priority Critical patent/SG10201603721TA/en
Publication of SG10201603721TA publication Critical patent/SG10201603721TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL], lymphokine activated killer cells [LAK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
SG10201603721TA 2016-05-10 2016-05-10 Anti-CTLA-4 Antibodies SG10201603721TA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG10201603721TA SG10201603721TA (en) 2016-05-10 2016-05-10 Anti-CTLA-4 Antibodies

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
SG10201603721TA SG10201603721TA (en) 2016-05-10 2016-05-10 Anti-CTLA-4 Antibodies
SG11201809857TA SG11201809857TA (en) 2016-05-10 2017-04-13 Anti-CTLA-4 Antibodies
KR1020187035791A KR20190015715A (en) 2016-05-10 2017-04-13 Anti-CTLA-4 antibody
CN201780029330.5A CN109563165A (en) 2016-05-10 2017-04-13 Anti- CTLA-4 antibody
US15/486,468 US9758583B2 (en) 2016-05-10 2017-04-13 Anti-CTLA-4 antibodies
JP2018559329A JP2019519208A (en) 2016-05-10 2017-04-13 Anti-CTLA-4 antibody
US16/099,652 US20190153097A1 (en) 2016-05-10 2017-04-13 Anti-CTLA-4 Antibodies
TW106112375A TW201739763A (en) 2016-05-10 2017-04-13 Anti-CTLA-4 antibodies
AU2017262448A AU2017262448A1 (en) 2016-05-10 2017-04-13 Anti-CTLA-4 antibodies
PCT/EP2017/058956 WO2017194265A1 (en) 2016-05-10 2017-04-13 Anti-CTLA-4 Antibodies
CA3023787A CA3023787A1 (en) 2016-05-10 2017-04-13 Anti-ctla-4 antibodies
EP17718870.3A EP3455255A1 (en) 2016-05-10 2017-04-13 Anti-ctla-4 antibodies

Publications (1)

Publication Number Publication Date
SG10201603721TA true SG10201603721TA (en) 2017-12-28

Family

ID=58609383

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201603721TA SG10201603721TA (en) 2016-05-10 2016-05-10 Anti-CTLA-4 Antibodies
SG11201809857TA SG11201809857TA (en) 2016-05-10 2017-04-13 Anti-CTLA-4 Antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201809857TA SG11201809857TA (en) 2016-05-10 2017-04-13 Anti-CTLA-4 Antibodies

Country Status (10)

Country Link
US (2) US20190153097A1 (en)
EP (1) EP3455255A1 (en)
JP (1) JP2019519208A (en)
KR (1) KR20190015715A (en)
CN (1) CN109563165A (en)
AU (1) AU2017262448A1 (en)
CA (1) CA3023787A1 (en)
SG (2) SG10201603721TA (en)
TW (1) TW201739763A (en)
WO (1) WO2017194265A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE6722018A1 (en) 2015-05-29 2018-04-19 Agenus Inc anti-CTLA-4 antibodies and methods of use thereof
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
WO2019056281A1 (en) * 2017-09-21 2019-03-28 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4 antibodies and uses thereof
WO2019092181A1 (en) 2017-11-10 2019-05-16 Agency For Science, Technology And Research Il2rbeta/common gamma chain antibodies

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0615451T3 (en) 1992-05-26 2006-04-24 Immunex Corp Novel cytokine that binds to CD30
KR100942863B1 (en) 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 Human ctla-4 antibodies and their uses
ITRM20010408A1 (en) 2001-07-10 2003-01-10 Univ Napoli Federico Ii Mini-human antibody cytotoxic to cancer cells that express the ErbB2 receptor.
CN1638800A (en) 2002-01-09 2005-07-13 米德列斯公司 Human monoclonal antibodies against CD30
EP2287195B1 (en) 2004-07-01 2019-05-15 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
SI2511297T1 (en) 2004-02-06 2015-07-31 Morphosys Ag Anti-CD38 human antibodies and uses therefor
EP2535355B1 (en) 2005-03-23 2019-01-02 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1 (PD-1) as well as methods of treating cancer using the anti-PD-1 antibodies alone or in combination with other immunotherapies
TWI461436B (en) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd Human monoclonal antibody human cd134 (ox40) and methods of making and using same
ES2661952T3 (en) 2006-08-04 2018-04-04 Medimmune Limited human antibodies against ERBB2
WO2008059491A1 (en) 2006-11-13 2008-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using sirna molecules directed against cd24
EP2129396B1 (en) 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
CA2706926A1 (en) 2007-11-30 2009-06-11 Bristol-Myers Squibb Company Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
KR20190069615A (en) 2008-12-09 2019-06-19 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2478110B1 (en) 2009-09-16 2016-01-06 Immunomedics, Inc. Class i anti-cea antibodies and uses thereof
SG183847A1 (en) 2010-03-04 2012-10-30 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
JP2013534813A (en) 2010-05-26 2013-09-09 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Anti cd133 antibody single chain variable fragments, and use thereof
CN103221427B (en) 2010-08-23 2016-08-24 德克萨斯州立大学董事会 Ox40 anti-antibody method and use thereof
RU2668170C2 (en) 2011-04-25 2018-09-26 Дайити Санкио Компани, Лимитед Anti-b7-h3-antibody
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
JP6271432B2 (en) 2011-09-30 2018-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Anti-ErbB3 antibody and uses thereof
EP2773651A4 (en) 2011-11-03 2015-08-12 Univ Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
AU2013312211B2 (en) 2012-09-07 2018-03-29 King's College London VISTA modulators for diagnosis and treatment of cancer
WO2014066532A1 (en) 2012-10-23 2014-05-01 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
EP2958942A1 (en) 2013-02-20 2015-12-30 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
WO2014160627A1 (en) 2013-03-25 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
SI3178849T1 (en) 2013-09-20 2019-06-28 Bristol-Myers Squibb Company Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments

Also Published As

Publication number Publication date
US20170226211A1 (en) 2017-08-10
US20190153097A1 (en) 2019-05-23
WO2017194265A1 (en) 2017-11-16
TW201739763A (en) 2017-11-16
US9758583B2 (en) 2017-09-12
CN109563165A (en) 2019-04-02
CA3023787A1 (en) 2017-11-16
JP2019519208A (en) 2019-07-11
EP3455255A1 (en) 2019-03-20
KR20190015715A (en) 2019-02-14
AU2017262448A1 (en) 2019-01-03
SG11201809857TA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
AP201709763A0 (en) Anti-lag3 antibodies and antigen-binding fragments
HK1217207A1 (en) Anti-c5 antibodies having improved pharmacokinetics -c5
TWI576353B (en) Multispecific antibodies
SG11201700207WA (en) Anti-pd-l1 antibodies and diagnostic uses thereof
SG11201701161QA (en) Anti-tigit antibodies
GB201406767D0 (en) Humanized anti-Tn-MUC1 antibodies anf their conjugates
IL256922D0 (en) Pd-l1 (" programmed death-ligand 1" ) antibodies
EP3177649A4 (en) Anti-pd-l1 antibodies
HUE041976T2 (en) Conjugated compounds comprising cysteine-engineered antibodies
IL256844D0 (en) Pd-1 antibodies
EP3332006A4 (en) Novel anti-pd-l1 antibodies
EP3307777A4 (en) Novel anti-pd-l1 antibodies
HK1231369A1 (en) Humanized or chimeric cd3 antibodies cd3
SG11201605580RA (en) Antibodies directed against interleukin-33 (il-33)
SG11201701040XA (en) Chimeric antigen receptors
IL248257D0 (en) Humanized antibodies against cd269 (bcma)
SG11201701623UA (en) Anti-her2 antibodies and immunoconjugates
EP3242894A4 (en) Anti-pd-l1 antibodies
EP3107582A4 (en) Ebola monoclonal antibodies
EP3334763A4 (en) Novel anti-pd-1 antibodies
SG11201701189TA (en) Sirp-alpha immunoglobulin fusion proteins
EP3204422A4 (en) Humanized anti-ox40 antibodies and uses thereof
SG11201703767XA (en) Anti-interleukin-33 antibodies and uses thereof
EP3182987A4 (en) Humanized anti-tau antibodies
IL247299D0 (en) Complement component c5 antibodies